Correlation of PDGF and TXA2 expression with platelet parameters and coagulation indices in chronic altitude sickness (CMS) patients

New Findings What is the central question of this study? Answer: Are PDGF and TXA2 expressions elevated in chronic altitude patients, and are they related to thrombosis in chronic altitude disease? What is the main finding and its importance? Answer: The expression of PDGF and TXA2 both in the bone marrow and peripheral blood of patients with chronic altitude disease is elevated, which is considered to be involved in the mechanism of thrombosis in patients with chronic altitude disease. Abstract Objective: The purpose of this study was to evaluate the expression of PDGF and TXA2 with platelet parameters and coagulation indices in chronic mountain sickness (CMS) patients and healthy individuals on a high-elevation plateau. Method: The levels of PDGF and TXA2 were examined in 22 CMS patients and 25 healthy individuals, and the association between platelet parameters and coagulation indices was investigated. Results: The MPV, PLT, PCT, and FDP characteristics of the CMS group were statistically different in the CMS compared to the control group (P<0.001). The levels of PDGF and TXA2 in the bone marrow and peripheral blood of CMS patients were significantly different (P<0.01) in comparison to the control group. The two factors had no statistically significant relationship with platelet parameters or coagulation indices (P>0.159). Conclusions: According to the current findings, platelets in CMS patients were activated, resulting in aberrant coagulation and PDGF and TXA2 expression, which could be due to physiological adjustments to the plateau's high altitude. To summarize, PDGF and TXA2 levels in CMS patients were not correlated with coagulation or platelet parameters, implying that the mechanism behind their increased expression warrants additional investigation. This article is protected by copyright. All rights reserved